immatics biotechnologies GmbH (NASDAQ:IMTXW) — Market Cap & Net Worth
Market Cap & Net Worth: immatics biotechnologies GmbH (IMTXW)
immatics biotechnologies GmbH (NASDAQ:IMTXW) has a market capitalization of $5.77 ($5.77) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32047 globally and #6449 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying immatics biotechnologies GmbH's stock price $0.00 by its total outstanding shares 9617 (9.62K). Also see balance sheet size of immatics biotechnologies GmbH for a full breakdown of the balance sheet.
immatics biotechnologies GmbH Market Cap History: 2020 to 2025
immatics biotechnologies GmbH's market capitalization history from 2020 to 2025. Data shows change from $27.70K to $5.77 (-83.89% CAGR). Also see immatics biotechnologies GmbH (IMTXW) cash flow conversion for how efficiently the company converts equity into cash flow.
immatics biotechnologies GmbH Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how immatics biotechnologies GmbH's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check immatics biotechnologies GmbH stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
immatics biotechnologies GmbH's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
immatics biotechnologies GmbH's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $27.70K | $31.25 Million | -$229.35 Million | 0.00x | N/A |
| 2021 | $42.22K | $34.76 Million | -$95.06 Million | 0.00x | N/A |
| 2022 | $24.14K | $172.83 Million | $37.51 Million | 0.00x | 0.00x |
| 2023 | $28.08K | $54.00 Million | -$96.99 Million | 0.00x | N/A |
| 2024 | $2.42K | $155.84 Million | $15.22 Million | 0.00x | 0.00x |
Competitor Companies of IMTXW by Market Capitalization
Companies near immatics biotechnologies GmbH in the global market cap rankings as of September 18, 2026. Review immatics biotechnologies GmbH (IMTXW) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to immatics biotechnologies GmbH by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
immatics biotechnologies GmbH Historical Marketcap From 2020 to 2025
Between 2020 and today, immatics biotechnologies GmbH's market cap moved from $27.70K to $ 5.77, with a yearly change of -83.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.77 | -99.76% |
| 2024 | $2.42K | -91.39% |
| 2023 | $28.08K | +16.33% |
| 2022 | $24.14K | -42.82% |
| 2021 | $42.22K | +52.43% |
| 2020 | $27.70K | -- |
End of Day Market Cap According to Different Sources
On Jun 29th, 2026 the market cap of immatics biotechnologies GmbH was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.77 USD |
| MoneyControl | $5.77 USD |
| MarketWatch | $5.77 USD |
| marketcap.company | $5.77 USD |
| Reuters | $5.77 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more